APP Pulse Episode 2: Hitting the Target: ADCs Explained

Shannon Westin, MD, MPH interviews two speakers from the Presidential Symposium at ESMO 2026 on Saturday, October 24. (Lorusso) LBA11 - Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 Study(Slomovitz) LBA12 - KEYNOTE-C93/GOG-3064/ENGOT-en15: Phase 3, Randomized, Open-Label Study of First-Line (1L) Pembrolizumab (Pembro) vs Carboplatin (C) + Paclitaxel (P) in Mismatch Repair-Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (a/rEC)(Gardner) 1256P - Endometrial cancer (EC): Patients (Pts) raise their voicesHost: Shannon Westin, MD, MPHGuests: Domenica Lorusso, MD, PhD, Brian Slomovitz, MD, Ginger Gardner, MD

Shannon Westin, MD, MPH interviews some of the abstract presenters and discusses the abstract she presented during an exciting afternoon session on Day 2 of ESMO 2026, Saturday, October 24. (Backes) 1239O - NRG-GY020: Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early-Stage High Intermediate Risk (HIR) Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer(Westin) LBA37 - Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): interim overall survival (OS) and safety from the randomised Phase 3 DUO-E/GOG-3041/ENGOT-EN10 study(Oaknin) LBA38 - Final overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervical cancer (R/M CC)Host: Shannon Westin, MD, MPHGuests: Floor Backes, MD, Ana Okanin, MD, PhD

Shannon Westin, MD, MPH talks to a few of the abstract presenters from a Rapid Oral session on Day 2 of ESMO 2026, Saturday, October 24. (Meric-Bernstam) 1245RO - Updated results from FONTANA: Torvutatug samrotecan (torvu-sam), a folate receptor α (FRα)-targeted antibody-drug conjugate (ADC), in patients (pts) with platinum-resistant ovarian cancer (PROC)\(Salutari) LBA41 - Mocertatug rezetecan (Mo-Rez) in patients with platinum-resistant ovarian cancer (PROC): Updated results with longer follow-up from the global BEHOLD-1 study(Kyi) 1246RO - Efficacy and safety of sofetabart mipitecan (Sofe-M), a folate receptor alpha (FRα) targeting antibody drug conjugate (ADC), plus bevacizumab (bev) in recurrent platinum (plat) sensitive ovarian cancer (PSOC)(Oaknin) 1247RO - Raludotatug Deruxtecan (R-DXd) + Bevacizumab (Bev) in Participants (Pts) With Platinum-Resistant Recurrent Ovarian Cancer (PROC): Results for Cohort B-1 of the Phase 1b/2 REJOICE-Ovarian02 StudyHost: Shannon Westin, MD, MPHGuests: Funda Meric-Bernstam, MD, Vanda Salutari, MD, Chrisann Kyi, MD, Ana Oaknin, MD, PhD

Shannon Westin, MD, MPH talks to Domenica Lorusso, MD, PhD and Fiona Simpkins, MD about the following abstracts presented in a Rapid Oral Session at ESMO 2026 on Friday, October 23. (Lorusso) 1241RO - Preliminary Efficacy of INCB123667 (CDK2 Inhibition) with Bevacizumab in Recurrent Epithelial Ovarian Cancer (rEOC)(Simpkins) 1242RO - Azenosertib in platinum-resistant ovarian cancer (PROC): overall survival analysis from Part 1b of the DENALI study (GOG-3066)Host: Shannon Westin, MD, MPHGuests: Domenica Lorusso, MD, PhD, Fiona Simpkins, MD

Clinical research is the backbone of advancing cancer care, and advanced practitioners are at the heart of it. This episode breaks down the fundamentals of clinical research, from study types and trial phases to key terms such as protocol, principal investigator, endpoints, informed consent, and hazard ratio. We explore common challenges in research participation, including patient hesitancy, mistrust, and complex protocols, and the unique and vital role APPs play in trial implementation: educating and counseling patients, assessing eligibility, managing toxicities, and coordinating with research nurses and study teams. We close with practical tips for getting involved and look at how advanced practitioners can be powerful advocates for their patients at the intersection of clinical care and discovery. Hosts: Nicole Dreibelbis, CRNP, WHNP-BC Guests: Sarah Huepenbecker, MD, MPH, Allison Walker, MD

Hosts Sarah Irish and Nicole Dreibelbis are joined by Megan Lanigan, CRNP, WHNP, AOCNP, and Kimberly Stout, NP, to discuss survivorship care in gynecologic oncology — what survivorship means for patients and providers, the programs and clinics their respective practices have put in place, and practical guidance for APPs looking to build or strengthen survivorship initiatives at their own institutions.Hosts: Nicole Dreibelbis, CRNP, and Sarah Irish, FNP-BC, AOCNP Guests: Megan Lanigan, CRNP, WHNP, AOCNP, and Kimberly Stout, NPAdditional Resources:https://www.sgo.org/wp-content/uploads/2026/09/Initiating-a-Survivorship-Program.pptxhttps://www.sgo.org/wp-content/uploads/2026/09/Survivorship-Work-Flow-Chart.docxhttps://www.sgo.org/wp-content/uploads/2026/09/survivorship-survey-central-PA.pdfhttps://www.sgo.org/wp-content/uploads/2026/09/GYN-Survivorship-Program-SOP-4.14.2023.docxhttps://www.sgo.org/wp-content/uploads/2026/09/TREATMENT-SUMMARY-EX.docxSurvivorship Toolkit | Society of Gynecologic OncologySurvivorship | Foundation For Women's Cancer

In this episode of APP Pulse, Julie Justice, CRNP, and Michelle Boisen, MD, join hosts Nicole Dreibelbis and Sarah Irish to discuss Enhanced Recovery After Surgery (ERAS) protocols and their impact on surgical outcomes in gynecologic oncology care. They dig into what ERAS looks like in practice, how it improves patient outcomes, and how APPs can champion implementation at their own institutions. Tune in for practical insights on driving adherence and building better recovery pathways for gynecologic oncology patients. Hosts: Nicole Dreibelbis, CRNP, and Sarah Irish, FNP-BC, AOCNP Guests: Julie Justice, CRNP, and Michelle Boisen, MD Additional Resources:Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 update - Gynecologic Oncology ERAS Patient Education: Factsheet and VideoWebinar: What is ERAS and how can it help usWebinar: Implementing ERAS, the nuts and bolts

ADC use is expanding, and APPs play a central role in counseling patients and in identifying and managing toxicities. This episode explores the evolving role of antibody-drug conjugates in gynecologic cancer treatment and highlights current evidence, clinical application and future directions for improving patient outcomes. It provides expert insights into how these target therapies are shaping the landscape of ovarian, endometrial and cervical cancer care. This episode will give APPs plain language they can use with patients, a framework for predicting and managing side effects, and insights on how dose reduction can preserve quality of life while maintaining response.Hosts: Nicole Dreibelbis, CRNP, WHNP-BC, Sarah Irish, DNP, APRN, FNP-BCGuest: Jennifer MacDonald, PharmD, BCOPSuggested Resource: https://www.sciencedirect.com/science/article/pii/S2352578923000103 

Hormone replacement in patients with gynecological cancer has always been a controversial topic. The guests on this episode help to debunk the myths and give guidance on how to have these important conversations and when to offer HRT to our patients.Hosts: Nicole Dreibelbis, CRNP, WHNP-BC, Sarah Irish, DNP, APRN, FNP-BCGuests: Jessie Dorne, PA, Rachel Frankenthal, PA-C, MPH, MSCPAdditional Resources:https://heatherhirschacademy.com/course/managing-hormone-therapy-for-gynecologic-cancer-survivors/

This episode features recent updates presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany. Lisa Rauh-Benoit, MD, MPH, and Michelle Boisen, MD discuss data presented for trials including DUO-O, Rina-S/RAINFOL-1 , TV 205 and more, highlighting the key takeaways and implications for practice. View the accompanying PDF resource developed by the SGO Education Committee here (https://connected.sgo.org/content/highlights-esmo-2025).